Overview

A Study to Determine the Safety and Efficacy of Rilpivirine in Treatment-naive Indian Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Status:
Terminated

Trial end date:
2021-06-28

Target enrollment:

Participant gender:

Summary

The primary purpose of the study is to evaluate the efficacy of rilpivirine (RPV)-based regimen in human immunodeficiency virus type 1 (HIV-1) infected, antiretroviral (ARV) treatment-naive participants, as determined by the percentage of virologic responders defined as having HIV-1 ribonucleic acid (RNA) less than 400 copies/ milliliter (mL) at Week 24.

Phase:

Phase 3

Details

Lead Sponsor:

Johnson & Johnson Pte Ltd

Treatments:

Lamivudine
Rilpivirine
Tenofovir